<DOC>
	<DOCNO>NCT00458081</DOCNO>
	<brief_summary>Primary objective : - To assess effect microalbuminuria level treatment rimonabant 20 mg versus placebo 12 month period . Secondary objective : - Percentage patient arm study whose level microalbuminuria decrease , stabilise , increase towards macroalbuminuria unchanged 12 month treatment rimonabant placebo . - To assess effect treatment rimonabant 20 mg versus placebo 12 month period : - Weight waist circumference . - Glycaemia profile : fasting glycaemia , fast insulinaemia HbA1c . - Lipid lipoprotein profile : triglyceride , total cholesterol , HDL-C , LDL-C , apolipoproteins A1 B . - Inflammatory marker - Adipocytokines . - Blood pressure . - Glomerular filtration rate . - To assess quality life mean questionnaire fill . - Safety parameter</brief_summary>
	<brief_title>Evaluation Rimonabant Impact Regression Asymptomatic Damage Caused Cardiovascular Risk Factors</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Albuminuria</mesh_term>
	<mesh_term>Rimonabant</mesh_term>
	<criteria>Body Mass Index &gt; 27 kg/m2 &lt; 40 kg/m2 . Waist circumference &gt; 102 cm men &gt; 88 cm woman . Microalbuminuria &gt; = 20 mg/g creatinine &lt; 300 mg/g creatinine least two three morning urine sample take 3 separate day prior baseline visit . Type 2 diabetes and/or dyslipidaemia . Breastfeeding pregnant woman expect become pregnant . Nonuse approve method contraception woman childbearing potential . History low calorie diet 3 month prior screen visit ( &lt; 1200 kcal/day ) . Change weight &gt; 5 kg 3 month prior screen visit . History surgery weight loss ( vertical band gastroplasty , gastric bypass , etc . ) History bulimia anorexia nervosa accord DSMIV definition . Any clinically significant endocrine disorder , opinion investigator , especially know alteration blood concentration TSH free T4 . Type 1 Diabetes Triglyceridaemia &gt; 400 mg/dl ( 4.52 mmol/l ) Severe renal dysfunction Chronic Hepatitis clinically know significant liver disease ALT and/or AST &gt; 3x upper limit normal range screen visit . Hypertension screen visit . Presence condition ( medical , include clinically significant abnormal laboratory test , physiological , social geographical ) actual anticipate investigator feel would compromise patient 's safety limit his/her successful participation study . History abuse alcohol substance ( except smoke ) . Hypersensitivity intolerance active ingredient excipients , lactose . Concomitant medication prior screen visit Administration treatment undergo clinical investigation ( drug medical device ) 30 day prior screen visit . Previous treatment rimonabant . Administration follow product 3 month prior screen visit Antiobesity drug ( , sibutramine orlistat ) . Other weight loss drug ( phentermine , amphetamine ) . Weight loss herbal preparation . Nicotinic acid , fibrates , bile acid sequestrants Omega 3 drug ( e.g . Omacor ) . Prolonged use ( week ) systemic corticosteroid neuroleptic Antidepressants ( include bupropion ) Insulin , thiazolidinediones , Î±glucosidase inhibitor , meglitinides group antidiabetic drug ( except combination biguanides sulfonylureas ) In type 2 diabetes patient , start change treatment sulfonylureas and/or metformin , 4 week prior screen visit . Start change treatment antihypertensive drug 12 week prior screen visit . Start change treatment statins and/or ezetimibe 8 week prior screen visit . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>